Gastric retained gabapentin dosage form
Granted: November 12, 2013
Patent Number:
8580303
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Methods of treatment using a gastric retained gabapentin dosage
Granted: September 10, 2013
Patent Number:
8529955
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
Methods of treatment using a gastric retained gabapentin dosage
Granted: July 2, 2013
Patent Number:
8475813
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
Methods of treatment using a gastric retained gabapentin dosage
Granted: May 14, 2013
Patent Number:
8440232
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
Gastric retained gabapentin dosage form
Granted: April 2, 2013
Patent Number:
8409613
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Granted: March 12, 2013
Patent Number:
8394408
Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Granted: February 19, 2013
Patent Number:
8377453
Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Granted: February 12, 2013
Patent Number:
8372432
Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
Gastric retained gabapentin dosage form
Granted: December 18, 2012
Patent Number:
8333992
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Gastric retained gabapentin dosage form
Granted: December 18, 2012
Patent Number:
8333991
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Methods for treating vasomotor symptoms using GABA analogs in a gastric retentive dosage form
Granted: December 11, 2012
Patent Number:
8329750
Methods for treating vasomotor symptoms associated with menopause are described.
Shell and core dosage form approaching zero-order drug release
Granted: December 11, 2012
Patent Number:
8329215
Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
Gastric retained gabapentin dosage form
Granted: July 31, 2012
Patent Number:
8231905
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Gastric retained gabapentin dosage form
Granted: June 5, 2012
Patent Number:
8192756
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Methods of treatment using a gastric retained gabapentin dosage
Granted: February 21, 2012
Patent Number:
8119166
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
Shell-and-core dosage form approaching zero-order drug release
Granted: October 25, 2011
Patent Number:
8043630
Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
Granted: July 12, 2011
Patent Number:
7976870
Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a…
Shell-and-core dosage form approaching zero-order drug release
Granted: June 15, 2010
Patent Number:
7736667
Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also promotes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to a size that is retained in the stomach during the postprandial or fed mode.
Gastric retained gabapentin dosage form
Granted: June 8, 2010
Patent Number:
7731989
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Methods of treatment using a gastric retained gabapentin dosage
Granted: November 3, 2009
Patent Number:
7612112
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
